Chronic Neuropathic Pain
Chronic neuropathic pain at 3 months is a secondary outcome measured with the DN4 questionnaire, an assessment that prior thoracic lidocaine studies have not systematically included. The trial's assessment of chronic neuropathic pain is li…
1 sources - 3 claims
Chronic neuropathic pain at 3 months is a secondary outcome measured with the DN4 questionnaire, an assessment that prior thoracic lidocaine studies have not systematically included. The trial's assessment of chronic neuropathic pain is limited because DN4 is used alone without concurrent measures of long-term pain intensity or functional interference. Intravenous lidocaine is hypothesised to reduce the transition from acute postoperative pain to chronic neuropathic pain by attenuating neuroinflammation and central sensitisation.